


consider next pathway step.



Pathway for treatment of Psoriatic Arthritis in adults.



Maximum of five sequential treatments per patient are routinely commissioned.





Version	4
Approved by	Hertfordshire & West Essex Area Prescribing Committee
Date approved / updated	Nov 2024
Developed by	Pharmacy and Medicines Optimisation Team Hertfordshire and West Essex (HWE) ICB with relevant HWE ICS stakeholders.
Review Date	This HWE APC recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available
Superseded version	 V1.0 Risankizumab added up to 5th line and guselkumab criteria amended, in line with NICE TA 803 and 815 and existing pathway principles. V2.0 Bimekizumab added up to 5th line in line with NICE TA 916 and existing pathway principles. Nov 2023 V3.0 Amended to remove note 7 'reduced dose interval of 4-weekly is not routinely commissioned for guselkumab'. Wording aligned with psoriasis pathway and text box advising updates to pathway.June 2024 V4.0 Addition of ustekinumab biosimilar and corresponding adjustment of order of choice according to cost Nov 2024

NICE recommends if patients and their clinicians consider a medicine to be one of a range of suitable treatments, the least expensive treatment should be chosen, taking into account administration costs, dosage, price per dose and commercial arrangements. Therefore, in line with this recommendation and HWE APC agreed principles the order of preference of treatments within this pathway will be updated accordingly as prices change or biosimilar medicines become available.